<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894214</url>
  </required_header>
  <id_info>
    <org_study_id>001533</org_study_id>
    <secondary_id>001533</secondary_id>
    <nct_id>NCT04894214</nct_id>
  </id_info>
  <brief_title>Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19</brief_title>
  <acronym>VICAR</acronym>
  <official_title>Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 - an Interventional Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Flow controlled ventilation (FCV) is a fairly new mode of mechanical ventilation, consisting&#xD;
      of a constant inspiratory and expiratory flow. Inspiration is thus comparable to volume&#xD;
      controlled ventilation (VCV). The actively controlled, constant flow during expiration is&#xD;
      unique. FCV is known to minimize dissipated energy to the lung [ref] and is therefore&#xD;
      supposed to aid in lung protective ventilation.&#xD;
&#xD;
      The VICAR study is designed as a prospective single cohort crossover trial. The intervention&#xD;
      consists of a sequence of respiratory modes: baseline pressure controlled ventilation (PCV)&#xD;
      during 5 minutes, followed by 30 minutes of FCV with an evone respirator (Ventinova Medical&#xD;
      B.V., Eindhoven, The Netherlands) and eventually 30 minutes of VCV. Every participant will&#xD;
      receive the intervention. Respiratory rate (RR), positive end-expiratory pressure (PEEP) and&#xD;
      inspiratory fraction of oxygen (FiO2) will be held constant. According to the manufacturers&#xD;
      guidelines, an I:E ratio of 1:1 will be pursued during FCV. During FCV, the respirator will&#xD;
      be set with the same PIP as during baseline PCV. For VCV, the same tidal volume as during&#xD;
      baseline PCV will be set.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial oxygen tension, PaO2 (mmHg)</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Arterial partial oxygen tension as measured on an arterial blood gas sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>P/F ratio or Horowitz index (mmHg)</measure>
    <time_frame>Post hoc calculation</time_frame>
    <description>Ratio of the arterial oxygen tension PaO2 (mmHg) divided by the inspiratory fraction of oxygen FiO2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SpO2 (%)</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Oxygen saturation as measured by pulse oxymetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FiO2</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Fraction of inspired oxygen as measured by the respirator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEEP (cmH2O)</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Positive end-expiratory pressure as measured by the respirator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pmean</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Mean airway pressure (cmH2O) as measured by the respirator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaCO2</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Arterial partial tension of carbon dioxide (mmHg) as measured on an arterial blood gas sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MV</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Minute volume (l/min) as measured by the respirator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TV</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Tidal volume (ml) as measured by the respirator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Respiratory rate (breaths per minute) as measured by the respirator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pplat</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Plateau airway pressure (cmH2O) as measured by the respirator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PIP</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Peak inspiratory airway pressure (cmH2O) as measured by the respirator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABPsys</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Systolic arterial blood pressure (mmHg) as measured by a pressure transducer on an arterial catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABPmean</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Mean arterial blood pressure (mmHg) as measured by a pressure transducer on an arterial catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABPdia</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Diastolic arterial blood pressure (mmHg) as measured by a pressure transducer on an arterial catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HR</measure>
    <time_frame>Approximately 1 hour (5 min. PCV + 30min. FCV + 30 min. VCV)</time_frame>
    <description>Heart rate (beats per minute) as measured on a 5-lead continuous electrocardiogram.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <condition>Respiration, Artificial</condition>
  <arm_group>
    <arm_group_label>Sequential &quot;baseline PCV&quot; - &quot;FCV&quot; - &quot;VCV&quot;</arm_group_label>
    <description>Each participant will be subjected to baseline pressure controlled ventilation (PCV) during 5 minutes, followed by 30 minutes of FCV with an evone respirator (Ventinova Medical B.V., Eindhoven, The Netherlands) and eventually 30 minutes of VCV. Respiratory rate (RR), positive end-expiratory pressure (PEEP) and inspiratory fraction of oxygen (FiO2) will be held constant. According to the manufacturers guidelines, an I:E ratio of 1:1 will be pursued during FCV. During FCV, the respirator will be set with the same PIP as during baseline PCV. For VCV, the same tidal volume as during baseline PCV will be set.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Arterial blood gas (ABG)</intervention_name>
    <description>Arterial blood gasses will be drawn during baseline PCV, and every 15 minutes during FCV and VCV respectively. pO2 (mmHg), pCO2 (mmHg) and pH will be recorded.</description>
    <arm_group_label>Sequential &quot;baseline PCV&quot; - &quot;FCV&quot; - &quot;VCV&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Recording of hemodynamic monitoring</intervention_name>
    <description>Hemodynamic parameters (invasive arterial blood pressure (mmHg) and heart rate (beats per minute)) will be recorded every 5 minutes.</description>
    <arm_group_label>Sequential &quot;baseline PCV&quot; - &quot;FCV&quot; - &quot;VCV&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Recording of respiratory monitoring</intervention_name>
    <description>Tidal volume (ml), respiratory rate (breaths per minute), minute volume (l/min), dynamic compliance (ml/cmH2O), resistance (cmH2O/l/min), plateau pressure (cmH2O), mean airway pressure (cmH2O), positive end-expiratory pressure (cmH2O), peak inspiratory pressure (cmH2O) and fraction of inspired oxygen will be recorded every 5 minutes.</description>
    <arm_group_label>Sequential &quot;baseline PCV&quot; - &quot;FCV&quot; - &quot;VCV&quot;</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Point-of-care arterial blood gas sampling. The sample will be disposed as biohazard material&#xD;
      after analysis is done.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients requiring mechanical ventilation for moderately severe ARDS (P/F ratio 100-200)&#xD;
        due to COVID-19 were recruited from a tertiary intensive care unit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  P/F-ratio: 100-200 (moderate ARDS)&#xD;
&#xD;
          -  SpO2 88-94%&#xD;
&#xD;
          -  PaO2 60-80 mmHg&#xD;
&#xD;
          -  COVID-19 positive on a PCR test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 40 kg/mÂ²&#xD;
&#xD;
          -  Prone ventilation&#xD;
&#xD;
          -  Already invasively mechanically ventilated for more than 10 days&#xD;
&#xD;
          -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Schepens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Tom Schepens, MD</investigator_full_name>
    <investigator_title>Principal investigator, Member of staff at the department of critical care, Doctor of Philosophy, Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Flow controlled ventilation (FCV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

